Novo Nordisk Shares Plunge 21% As Ozempic Sales Are Expected To Slow
July 29, 2025
9,675
96
13
1.13%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Forbes Episodes Around July 29, 2025
See what was published immediately before and after this episode.
2:11Now PlayingNovo Nordisk Shares Plunge 21% As Ozempic Sales Are Expected To Slow
YouTube Description
as posted by the channelShares of Wegovy and Ozempic maker Novo Nordisk fell more than 21% Tuesday, pacing what would be the stock’s largest plunge since the 1980s after the Danish pharmaceutical firm cut its full-year guidance for sales and profit, as growth for its obesity and weight loss treatments are expected to slow in the U.S.
Read the full story on Forbes
Subscribe to FORBES
Fuel your success with Forbes. Gain unlimited access to premium journalism, including breaking news, groundbreaking in-depth reported stories, daily digests and more. Plus, members get a front-row seat at members-only events with leading thinkers and doers, access to premium video that can help you get ahead, an ad-light experience, early access to select products including NFT drops and more:
Stay Connected
Forbes newsletters
Forbes on Facebook
Forbes Video on Twitter
Forbes Video on Instagram
More From Forbes
Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.